UNC Eshelman School of Pharmacy, Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
Auto-generated profile, based on publicly available information
Travis Maxfield
UNC Eshelman School of Pharmacy, Center for Integrative Chemical Biology and Drug Discovery, Division of Chemical Biology and Medicinal Chemistry, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA
DNA-encoded library (DEL) technology has become a powerful tool in modern drug discovery. Fully harnessing its potential requires the use of extensive computational methodologies, which are often available only through proprietary software. This restricts accessibility for small teams lacking robust informatics support, hindering the growth of the technology. Here, we present DELi, an open-source DEL informatics platform designed for library design, NGS decoding and calling, and enrichment analysis. DELi supports a simple and easy to understand configuration setup to present a straightforward user interface. To showcase its capabilities, we used DELi to design an in-house custom, benzimidazole-based DEL (UNC DEL006), and performed proof-of-concept selection experiments against Bromodomain-containing Protein 4 (BRD4). The DELi decoding and analysis modules identified top-performing compounds, leading to the off-DNA synthesis of UNC11951, which was confirmed as a nanomolar BRD4 binder via isothermal titration calorimetry (ITC) and differential scanning fluorimetry (DSF). These results demonstrate DELi as an effective tool for DEL design and analysis. Furthermore, its open-source nature will promote ongoing development and contributions from the DEL community to expand its applications and capabilities, making DEL technology more widely accessible. Abstract Figure:
DNA-encoded libraries (DELs) are powerful tools for initial hit identification, yet the combinatorial chemistries and building block choices used in their construction can restrict chemical space coverage and hit drug-likeness, limiting efficient hit expansion. Generative artificial intelligence (AI), by contrast, can in principle explore drug-like chemical space around any given compound, but it often struggles with the synthesizability of generated molecules and requires a set of validated hits to initiate exploration. Here, we present a synergistic methodology that overcomes these mutual limitations by leveraging experimentally validated DEL data to initialize and bias an AI-powered virtual screening pipeline, expanding initial DEL hits with both de novo and purchasable compounds from ultra-large chemical libraries. Using this approach, we identified novel, commercially available hits from the Enamine REAL Space for the chromatin reader protein 53BP1 and validated them in a time-resolved fluorescence resonance energy transfer (TR-FRET) displacement assay. Three compounds demonstrated TR-FRET IC50 values ≤50 µM, while 11 exhibited IC50 values ≤100 µM. Critically, the AI-nominated hits exhibited greater chemical diversity, improved drug-likeness, and were readily purchasable off-the-shelf compared to compounds from the initial DEL selection. This work demonstrates a streamlined platform in which empirical DEL data and generative chemistry models are combined to enable rapid hit expansion from initially screened libraries into diverse, commercially available chemical matter.